Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263178 | 1.00 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL19970649 | 1.00 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL2562479 | 1.00 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1561831 | 1.00 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL4833427 | 0.96 | CA1 (0.42) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL5999732 | 0.96 | CA1 (0.42) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL23292518 | 0.96 | CA1 (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL2290678 | 0.96 | CA1 (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1479599 | 0.96 | CA1 (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1674203 | 0.96 | CA1 (0.44) | CA1CA2CA7CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843300-B | Crystalline polymorphic forms of a compound | 福斯特因公司 | 2021-08-27 | — | — | CN | claimed |
| EP-3515454-B1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOSTIN (FR) | 2020-11-11 | — | — | EP | claimed |
| US-10597414-B2 | Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-OXO-2λ5-[1,2]oxaphosphinane | PHOST'IN (FR) | 2020-03-24 | — | — | US | claimed |
| US-20190330252-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-0X0-2LAMBDA5-[l ,2]0XAPHOSPHINANE | PHOST'IN (FR) | 2019-10-31 | — | — | US | claimed |
| EP-3515454-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOST'IN (FR) | 2019-07-31 | — | — | EP | claimed |
| WO-2018054925-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOST'IN (FR) | 2018-03-29 | — | — | WO | claimed |
| EP-3295944-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOST'IN (FR) | 2018-03-21 | — | — | EP | claimed |
| CN-109843300-B | Crystalline polymorphic forms of a compound | 福斯特因公司 | 2021-08-27 | — | — | CN | disclosed |
| EP-3515454-B1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOSTIN (FR) | 2020-11-11 | — | — | EP | disclosed |
| US-10597414-B2 | Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-OXO-2λ5-[1,2]oxaphosphinane | PHOST'IN (FR) | 2020-03-24 | — | — | US | disclosed |
| US-20190330252-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-0X0-2LAMBDA5-[l ,2]0XAPHOSPHINANE | PHOST'IN (FR) | 2019-10-31 | — | — | US | disclosed |
| EP-3515454-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOST'IN (FR) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054925-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOST'IN (FR) | 2018-03-29 | — | — | WO | disclosed |
| EP-3295944-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOST'IN (FR) | 2018-03-21 | — | — | EP | disclosed |
| US-7838508-B2 | 4′-thio-L-xyloy furanosyl nucleosides, precursors thereof, preparation and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2010-11-23 | — | — | US | disclosed |
| US-20070112004-A1 | 4'-THIO-L-XYLOY FURANOSYL NUCLEOSIDES, PRECURSORS THEREOF, PREPARATION AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2007-05-17 | — | — | US | disclosed |
| US-6914061-B2 | 4′-thio-L-xylofuranosyl nucleosides, precursors thereof, preparation and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2005-07-05 | — | — | US | disclosed |
| US-20030144235-A1 | Anticarcinogenic agents for treating cancer, a viricides for viral diseases, inhibit DNA replication | SOUTHERN RESEARCH INSTITUTE | 2003-07-31 | — | — | US | disclosed |
| WO-2001066118-A1 | 4'-THIO-L-XYLO FURANOSYL NUCLEOSIDES, PRECURSORS THEREOF, PREPARATION AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2001-09-13 | — | — | WO | disclosed |
| US-4021542-A | Derivatives of hydrazino-monosaccharides and aldohexoses which are useful as intermediates for preparing compounds or as compounds which lower the uric acid | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144235-A1 | Anticarcinogenic agents for treating cancer, a viricides for viral diseases, inhibit DNA replication | POLL, PCNA, YWHAZ | CA1 4275/4885CA2 1966/4885CA7 2197/4885 |
| US-20070112004-A1 | 4'-THIO-L-XYLOY FURANOSYL NUCLEOSIDES, PRECURSORS THEREOF, PREPARATION AND USE THEREOF | POLL, PNP, UNG | CA1 4751/4885CA2 4173/4885CA7 3358/4885 |
| US-20190330252-A1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-0X0-2LAMBDA5-[l ,2]0XAPHOSPHINANE | CYP3A5, CYP4B1, SF3B5 | CA1 3465/4885CA2 3204/4885CA7 3807/4885 |
| US-10597414-B2 | Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-OXO-2λ5-[1,2]oxaphosphinane | IPO5, SF3B5, CYP3A5 | CA1 3517/4885CA2 3838/4885CA7 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.